Mucosis Announces New Scientific Advisory Board

Groningen, the Netherlands, November 15, 2011 / B3C newswire / – Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. today announced that it has appoint­ed pro­fes­sors Jiri Mestecky, M.D., Ph.D.; Willem van Eden, M.D., Ph.D.; and Peter J. Openshaw, M.B., B.S., Ph.D., F.Med.Sci., to its new­ly formed Scientific Advisory Board.
Dr. Mestecky is with the Department of Microbiology and Medicine at the University of Alabama, Birmingham, USA. His research is focused on mol­e­c­u­lar and cel­lu­lar inter­ac­tions that induce and reg­u­late the mucos­al immune sys­tem. Dr. van Eden is with the Department of Infectious Diseases and Immunology of the Veterinary Faculty, Utrecht University, the Netherlands. His research is focused on vac­cines, infec­tious dis­eases and chron­ic inflam­ma­tion. Dr. Openshaw is pro­fes­sor of exper­i­men­tal med­i­cine and the direc­tor of the Centre for Respiratory Infection at the National Heart and Lung Institute, Imperial College, London, UK and an hon­orary con­sul­tant physi­cian at the Imperial College Healthcare NHS Trust. His research is focused on the immunol­o­gy of the lung, viral lung dis­ease, vac­ci­na­tion and immune-patho­gen­e­sis of viral dis­ease.
“We have brought togeth­er an impres­sive group of inter­na­tion­al experts in virol­o­gy, vac­ci­nol­o­gy and mucos­al immunol­o­gy to sup­port the devel­op­ment of our pipeline of vac­cine can­di­dates,” com­ment­ed Kees Leenhouts, CSO of Mucosis. “This Board will pro­vide valu­able advice and coun­sel as our vac­cine can­di­dates progress through devel­op­ment and clin­i­cal test­ing. We thank this dis­tin­guished group for their par­tic­i­pa­tion and wel­come their insights and con­tri­bu­tions to our future suc­cess.”

Leave a Reply

Your email address will not be published. Required fields are marked *